REG-Arix Bioscience PLC Corporate update from portfolio company Harpoon Therapeutics

Arix BioscienceAnnouncement

14/03/2022 11:45

============

   Arix Bioscience PLC (ARIX)
   Corporate update from portfolio company Harpoon Therapeutics

   14-March-2022 / 11:32 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                                        

   PRESS RELEASE

    

                              Arix Bioscience plc

                                        

          Corporate update from portfolio company Harpoon Therapeutics

    

   LONDON, 14 March 2022: Arix Bioscience plc ("Arix", LSE: ARIX), a global
   venture capital company focused on investing in and building breakthrough
   biotech companies, notes the recent announcement from Harpoon
   Therapeutics, Inc. (Nasdaq: HARP) of its financial results for the fourth
   quarter and full year of 2021, in which the company provided a corporate
   update.

    

   Following a thorough analysis of its HPN424 data, including clinical
   results to date, the company decided to discontinue the phase 1/2 dose
   escalation study for HPN424 in patients with metastatic
   castration-resistant prostate cancer. The discontinuation will allow
   Harpoon to concentrate on HNP328, in development for tumours associated
   with delta like ligand 3 (DLL3) expression, and HPN 217 for BCMA.

    

   Earlier in March, Harpoon announced the granting of Orphan Drug
   Designation for HPN328 in small cell lung cancer and Fast Track
   designation for HPN2178 in relapsed, refractory multiple myeloma. Studies
   to determine the recommended phase 2 dose for both candidates are expected
   to complete this year.

    

   The full text of the Harpoon announcement can be accessed  1 here.

    

    

                                      ENDS 

                                        

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

    2 ir@arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil

   +44 (0)20 7250 1446

    3 arix@powerscourt-group.com

    

    

   About Arix Bioscience plc

   Arix Bioscience plc is a global venture capital company focused on
   investing in and building breakthrough biotech companies around
   cutting-edge advances in life sciences.

    

   We collaborate with exceptional entrepreneurs and provide the capital,
   expertise and global networks to help accelerate their ideas into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting growth phase of our industry to a broader range of
   investors.  4 www.arixbioscience.com

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  PFU
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   148920
   EQS News ID:    1301829


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    5 fncls.ssp?fn=show_t_gif&application_id=1301829&application_name=news&site_id=reuters8

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=1fafd211b4e2e833be702085ef695098&application_id=1301829&site_id=reuters8&application_name=news
   2. mailto:ir@arixbioscience.com
   3. mailto:arix@powerscourt-group.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0e82cce39f5bc66fe0ead5d02956d352&application_id=1301829&site_id=reuters8&application_name=news


============